CV Sciences (OTCMKTS:CVSI) and Cyanotech (NASDAQ:CYAN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Earnings and Valuation
This table compares CV Sciences and Cyanotech’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CV Sciences||$48.24 million||8.73||$10.00 million||$0.09||46.67|
|Cyanotech||$30.20 million||0.50||-$3.60 million||N/A||N/A|
This is a breakdown of recent recommendations and price targets for CV Sciences and Cyanotech, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CV Sciences presently has a consensus target price of $8.50, indicating a potential upside of 102.38%. Given CV Sciences’ higher probable upside, research analysts plainly believe CV Sciences is more favorable than Cyanotech.
This table compares CV Sciences and Cyanotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
0.1% of CV Sciences shares are held by institutional investors. Comparatively, 13.0% of Cyanotech shares are held by institutional investors. 10.1% of CV Sciences shares are held by company insiders. Comparatively, 27.1% of Cyanotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
CV Sciences has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
CV Sciences beats Cyanotech on 8 of the 11 factors compared between the two stocks.
About CV Sciences
CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. Cyanotech Corporation sells its products as packaged consumer products through distributors, retailers, and online channels, as well as directly to consumers; and in bulk quantities to manufacturers, formulators, and distributors. The company was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.